Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna, COVID-19 Vaccine
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
Northwestern University Sues Moderna Over Spikevax Vaccine
Northwestern University sued vaccine maker Moderna, Inc. on Wednesday, October 16, in the U.S. District Court for the District of Delaware, alleging infringement of three patents the school says cover technology key to the delivery method for Moderna’s groundbreaking messenger-RNA (mRNA) COVID-19 vaccine.
GSK takes mRNA patent fight to Moderna, suing over vaccines for COVID and RSV
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-ba | GSK is targeting Moderna in a pair of lawsuits claiming the mRNA specialist violated multiple patents with its vaccines Spikevax and mRESVIA.
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
Northwestern sues Moderna for alleged patent infringement in COVID shots
Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to combat the pandemic.
British drugmaker sues Moderna for patent infringement related to mRNA vaccines
A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.
4h
on MSN
Moderna, Inc. (MRNA): Worst Performing NASDAQ Stock in 2024
We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...
1d
on MSN
BioNTech and Moderna: A tale of two mRNA developers
Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...
news.stocktradersdaily
8h
(MRNA) Pivots Trading Plans and Risk Controls
Check the time stamp on this data. Updated AI-Generated Signals for Moderna Inc. (MRNA) available here: MRNA.
pharmaphorum
3d
GSK turns its guns on Moderna in mRNA jab patent dispute
The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...
2d
Moderna (MRNA) Receives a Hold from Jefferies
Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...
bovnews
1d
Why Moderna Inc (MRNA) Stock is Currently -10.18% Off from Its 20-Day SMA?
On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $54.82 which represents a decrease of $-2.64 or -4.59% from the prior close of $57.46. The stock opened at $57.08 and touched a ...
devdiscourse
3d
Patent Wars: GSK Takes on Moderna Over mRNA Innovations
GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to ...
23h
mRNA licensing agreements surge 800% amid GSK lawsuits
Considering the reasons behind the jump in licensing deal values, Chan added: “Licensing agreement deal values for mRNA-based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback